Biology and treatment of Burkitt's lymphoma
Biology and treatment of Burkitt's lymphoma
复制标题
DOI：
10.1097/moh.0b013e3281bccdee
复制
发表时间：
2007-07-01
影响因子：
3.2
通讯作者：
Dang, Chi V.
中科院分区：
文献类型：
--
作者：
Yustein, Jason T.;Dang, Chi V.
伯基特淋巴瘤是一种独特的血液系统恶性肿瘤，其生物学特性，包括异常表达的MYC癌基因，其需要强化治疗方案显着。本文就Burkitt's淋巴瘤的分子生物学特征、治疗方法及进展进行综述，为Burkitt's淋巴瘤的生物学及治疗提供了新的思路。微阵列技术最近已被用于定义伯基特淋巴瘤的分子基因表达特征，该特征允许将淋巴瘤与其他形式的非霍奇金淋巴瘤如弥漫性大B细胞淋巴瘤区分开。最近的进展，在使用生物制剂，如利妥昔单抗，也允许减少治疗毒性，同时仍然提供可比的生存结果为patient.Summary伯基特淋巴瘤是一个有趣的成熟B细胞非霍奇金淋巴瘤，有许多不同的特点和临床变异取决于因素，如地理位置，免疫状态和患者的年龄。虽然MYC癌基因的作用已经得到了很好的研究，但我们现在才认识到这种疾病的定义分子特征，并利用这些进展来改善患者的治疗选择。
Purpose of review Burkitt's lymphoma is a unique hematological malignancy remarkable for its biological characteristics, including aberrant expression of the MYC oncogene, and its requirement for intensive treatment regimens. This review will focus on those features, and discuss recent advances in the molecular biology and advancing treatment options for the disease.Recent findings Advances in molecular biology have provided many new insights into the biology and treatment options for Burkitt's lymphoma. Microarray technology has recently been used to define a molecular gene expression signature for Burkitt's lymphoma, This signature allows for the differentiation of lymphoma from other forms of non-Hodgkin's lymphoma such as diffuse large B-cell lymphoma. Recent advances in the use of biological agents, such as rituximab, have also allowed for a reduction in treatment toxicities while still offering comparable survival outcomes for patients.Summary Burkitt's lymphoma is an interesting mature B-cell non-Hodgkin's lymphoma that has numerous distinct features and clinical variants depending on factors such as geographical location, immunological status and patient's age. Although the role of the MYC oncogene has been well studied, we are only now appreciating the defining molecular characteristics of this disease, and using these advances to improve treatment options for patients.